REFERENCES
- George JN, Nester CM. Syndromes of thrombotic microangiopathy. N
Engl J Med . 2014;371(7):654-666.
- Van Dorland HA, Taleghani MM, Sakai K, et al. The International
Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings
at enrollment until 2017. Haematologica .
2019;104(10):2107-2115.
- Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR,
George JN. Children and adults with thrombotic thrombocytopenic
purpura associated with severe, acquired Adamts13 deficiency:
comparison of incidence, demographic and clinical
features. Pediatr Blood Cancer . 2013;60(10):1676-1682.
- Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN.
Survival and relapse in patients with thrombotic thrombocytopenic
purpura. Blood . 2010;115(8):1500-1662.
- Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and
management of thrombotic thrombocytopenic purpura and other thrombotic
microangiopathies. Br J Haematol . 2012;158(3):323-335.
- Dane K, Chaturvedi S. Beyond plasma exchange: novel therapies for
thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol
Educ Program . 2018;2018(1):539-547.
- Matsumoto M, Fujimura Y, Wada H, et al. Diagnostic and treatment
guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in
Japan. Int J Hematol . 2017;106(1):3-15.
- Khan S, Landry K, Umyarova E. Caplacizumab treatment for acquired
refractory thrombotic thrombocytopenic purpura [published online
ahead of print, 2020 Aug 1]. Br J Haematol .
2020;10.1111/bjh.16977.
- Besnerais M, Veyradier A, Benhamou Y, Coppo P. Caplacizumab: a change
in the paradigm of thrombotic thrombocytopenic purpura
treatment. Expert Opin Biol Ther . 2019;19(11):1127-1134.
- Gómez-De León A, Villela-Martínez LM, Yáñez-Reyes JM, Gómez-Almaguer
D. Advances in the treatment of thrombotic thrombocytopenic purpura:
repurposed drugs and novel agents. Expert Rev Hematol .
2020;13(5):461-470.
- Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment
of thrombotic thrombocytopenic purpura. J Thromb Haemost.
2020;18(10):2496-2502.
- Paydary K, Banwell E, Tong J, Chen Y, Cuker A. Diagnostic accuracy of
the PLASMIC score in patients with suspected thrombotic
thrombocytopenic purpura: A systematic review and meta-analysis.
Transfusion. 2020 Sep;60(9):2047-2057.
- Bommer, Martin et al. “The Differential Diagnosis and Treatment of
Thrombotic Microangiopathies.” Deutsches Arzteblatt
international vol. 115,19 (2018): 327-334.
- Stanley M, Michalski JM. Thrombotic Thrombocytopenic Purpura (TTP).
In: StatPearls . Treasure Island (FL): StatPearls Publishing;
August 16, 2020.
- Dane K, Chaturvedi S. Beyond plasma exchange: novel therapies for
thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ
Program. 2018;2018(1):539-547.
- Wieland I, Kentouche K, Jentzsch M, Lothschütz D, Graf N, Sykora KW.
Long-term remission of recurrent thrombotic thrombocytopenic purpura
(TTP) after Rituximab in children and young adults. Pediatr
Blood Cancer . 2015;62(5):823-829.
- Schleinitz N, Ebbo M, Mazodier K, Poullin P, Bernit E, Veit V,
Veyradier A, Fakhouri F, Kaplanski G, Harle JR. Rituximab as
preventive therapy of a clinical relapse in TTP with ADAMTS13
inhibitor. Am J Hematol. 2007 May;82(5):417-8.
- Schleinitz N, Ebbo M, Mazodier K, Poullin P, Bernit E, Veit V,
Veyradier A, Fakhouri F, Kaplanski G, Harle JR. Rituximab as
preventive therapy of a clinical relapse in TTP with ADAMTS13
inhibitor. Am J Hematol. 2007 May;82(5):417-8.
- Elverdi T, Eskazan AE. Caplacizumab as an emerging treatment option
for acquired thrombotic thrombocytopenic purpura. Drug Des Devel Ther.
2019 Apr 17;13:1251-1258.
- Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga
JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De
Winter H, Zeldin RK; HERCULES Investigators. Caplacizumab Treatment
for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019
Jan 24;380(4):335-346.
- Kaczmarek V, Holle J, Astudillo R, Kempf C, Bufler P, Müller D.
Caplacizumab for relapsing thrombotic thrombocytopenic
purpura. Pediatr Nephrol . 2019;34(9):1625-1628.
- Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Bigé N, Poullin
P, Provôt F, Martis N, Presne C, Moranne O, Benainous R, Dossier A,
Seguin A, Hié M, Wynckel A, Delmas Y, Augusto JF, Perez P, Rieu V,
Barbet C, Lhote F, Ulrich M, Rumpler AC, de Witte S, Krummel T,
Veyradier A, Benhamou Y. A regimen with caplacizumab,
immunosuppression, and plasma exchange prevents unfavorable outcomes
in immune-mediated TTP. Blood. 2021 Feb 11;137(6):733-742.
- Dutt T, Shaw RJ, Stubbs M, Yong J, Bailiff B, Cranfield T, Crowley MP,
Desborough M, Eyre TA, Gooding R, Grainger J, Hanley J, Haughton J,
Hermans J, Hill Q, Humphrey L, Lowe G, Lyall H, Mohsin M, Nicolson
PLR, Priddee N, Rampotas A, Rayment R, Rhodes S, Taylor A, Thomas W,
Tomkins O, Van Veen JJ, Lane S, Toh CH, Scully M. Real-world
experience with caplacizumab in the management of acute TTP. Blood.
2021 Apr 1;137(13):1731-1740.
- George JN, Sandler SA, Stankiewicz J. Management of thrombotic
thrombocytopenic purpura without plasma exchange: the Jehovah’s
Witness experience. Blood Adv. 2017 Oct 30;1(24):2161-2165.
- Chander DP, Loch MM, Cataland SR, George JN. Caplacizumab Therapy
without Plasma Exchange for Acquired Thrombotic Thrombocytopenic
Purpura. N Engl J Med. 2019 Jul 4;381(1):92-94.